Immune treatment company Therapeutics Solution International Inc (OTC Markets:TSOI) revealed on Wednesday a publication from the University of Miami, demonstrating intravenous administration of JadiCells results in a significant survival improvement in COVID-19 patients.

The company added that the JadiCell stem cells used for treating brain injury significantly increased the survival of COVID-19 patients in double Blind FDA Clinical Trial. The 24 patients clinical trial validated superior anti-inflammatory and regenerative properties of JadiCell.

Under the Phase 1/2 double blind, placebo-controlled trial, the company treated 12 advanced COVID-19 patients with 100m JadiCells intravenously at days zero and three and 12 patients received placebo control. At 28 days 91% of JadiCell treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell administration.

According to the company, the JadiCells are a type of "supercharged" mesenchymal stem cells which have been demonstrated by the company, as well as independent academic and private institutions to possess superior therapeutic activity as compared to other stem cells.